Truist analyst Samuel Brodovsky upgraded Vericel to Buy from Hold with a price target of $51, up from $39. The analyst says stock’s valuation does not reflect Vericel’s growth acceleration potential and coming profit inflection. The firm increased estimates tor elect greater confidence in NexoBrid and the coming MACI arthroscopic launch. Truest expects revenue reacceleration in 2024 and 2025 will coincide with a profit inflection, “which tends to be a recipe for outperformance in SMID MedTech.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VCEL:
- Vericel price target raised to $42.40 from $40 at Ladenburg
- Vericel price target raised to $46 from $44.50 at H.C. Wainwright
- Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
- Vericel sees 2023 revenue $197.5M, consensus $195.04M
- Vericel sees Q4 revenue $65M, consensus $62.6M
